Zhu et al. prospectively evaluated an MRD-directed (using RT-PCR for RUNX1) consolidation approach for 116 patients with t(8;21) AML who were in first CR after induction chemotherapy [142]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.